Certara to acquire Chemaxon for £70m.

Certara, a company specializing in model-informed drug development, agreed to acquire Chemaxon, a provider of cheminformatics software, for £70m. “The combination of Chemaxon and Certara unites two complementary businesses with a shared mission of reducing drug development costs and risks to develop new medicines faster. Together, we can enhance prediction and analytical capabilities in drug discovery by leveraging biosimulation and generative AI,” William Feehery, Centara CEO.